Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Finished Goods (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Finished Goods data on record, last reported at $20.2 million in Q3 2025.

  • For Q3 2025, Finished Goods rose 23.13% year-over-year to $20.2 million; the TTM value through Sep 2025 reached $20.2 million, up 23.13%, while the annual FY2024 figure was $17.8 million, 17.12% up from the prior year.
  • Finished Goods reached $20.2 million in Q3 2025 per COLL's latest filing, roughly flat from $20.2 million in the prior quarter.
  • Across five years, Finished Goods topped out at $36.9 million in Q1 2022 and bottomed at $9.5 million in Q2 2021.
  • Average Finished Goods over 5 years is $16.5 million, with a median of $15.2 million recorded in 2023.
  • Peak YoY movement for Finished Goods: soared 280.78% in 2022, then crashed 62.81% in 2023.
  • A 5-year view of Finished Goods shows it stood at $12.7 million in 2021, then rose by 27.77% to $16.2 million in 2022, then decreased by 6.29% to $15.2 million in 2023, then grew by 17.12% to $17.8 million in 2024, then increased by 13.64% to $20.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $20.2 million in Q3 2025, $20.2 million in Q2 2025, and $18.5 million in Q1 2025.